Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 615 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Musculoskeletal Tumors Clear all
Completed Phase 2 Interventional

Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease

NCT00004409
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase
Drug
Lead sponsor
State University of New York
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
2
States / cities
Palo Alto, California • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT01207492
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions
nilotinib
Drug
Lead sponsor
Andrew J. Wagner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Santa Monica, California • Stanford, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia

NCT03736564
View directory record Official record
Conditions
Osteomalacia
Interventions
68Ga-DOTATATE PET/CT
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 9, 2026, 8:58 AM EDT
Terminated No phase listed Observational

Cyberknife Radiosurgery and Quality of Life

NCT01163539
View directory record Official record
Conditions
Bone Cancer, Central Nervous System Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 9, 2026, 8:58 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors

NCT02366312
View directory record Official record
Conditions
Keratocystic Odontogenic Tumor
Interventions
vismodegib
Drug
Lead sponsor
NYU College of Dentistry
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 9, 2026, 8:58 AM EDT
Suspended No phase listed Observational

Duke Spine Outcome Study (DSOS)

NCT04217525
View directory record Official record
Conditions
Spinal Tumor, Spinal Disorder
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 9, 2026, 8:58 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging for 18F-NaF Uptake

NCT07284563
View directory record Official record
Conditions
Healthy Volunteer, Bone Alteration, Bone and Joint Cancer, Bone and Joint Infection, Arthritis
Interventions
18F-NaF
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Phase 2 Interventional

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

NCT00130962
View directory record Official record
Conditions
Neuroma
Interventions
ALGRX 4975
Drug
Lead sponsor
AlgoRx Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Owings Mills, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2005 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor
Interventions
Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 9, 2026, 8:58 AM EDT
Completed No phase listed Observational

Cardiac Amyloidosis Screening at Trigger Finger Release

NCT03886155
View directory record Official record
Conditions
Amyloidosis, Trigger Finger, Transthyretin Amyloidosis, Primary Amyloidosis of Light Chain Type
Interventions
Biopsy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 9, 2026, 8:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

NCT00540566
View directory record Official record
Conditions
Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevi, Congenital Nevi, Seborrheic Keratosis, Paget's Disease, Dermatofibroma, Kaposi's Sarcoma, Port Wine Stain, Hemangioma, Tattoos, Scleroderma, Burns
Interventions
Optical Biopsy imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Phase 1 Interventional

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

NCT01928459
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
BGJ398, BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Tampa, Florida • Ann Arbor, Michigan • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 9, 2026, 8:58 AM EDT
Completed No phase listed Observational

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

NCT05421442
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38,396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lawrenceville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 9, 2026, 8:58 AM EDT
Withdrawn Phase 2 Interventional

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

NCT02747797
View directory record Official record
Conditions
Advanced Cancer
Interventions
Lucitanib
Drug
Lead sponsor
Teresa Helsten, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 9, 2026, 8:58 AM EDT
Not yet recruiting Not applicable Interventional

Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia

NCT06264362
View directory record Official record
Conditions
Pain, Chronic, Dementia, Mild, Mobility Limitation, Physical Disability, Osteo Arthritis Knee, Mild Cognitive Impairment
Interventions
Tailored Physical Activity Program
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Phase 1 Interventional Results available

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

NCT03291288
View directory record Official record
Conditions
Drug Interaction Potential
Interventions
Tolbutamide, Midazolam, Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 9, 2026, 8:58 AM EDT
Not yet recruiting Phase 3 Interventional

DEPART Study at Yale

NCT07661342
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
Radiation Therapy
Radiation
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Greenwich, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

NCT04754399
View directory record Official record
Conditions
Arthralgia, Breast Cancer
Interventions
Cannabidiol (CBD)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 9, 2026, 8:58 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

NCT05312411
View directory record Official record
Conditions
Osteosarcoma
Interventions
SCRI-E2CAR_EGFRtv1, UB_TT170
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 8:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors

NCT00954564
View directory record Official record
Conditions
Arthralgia, Breast Cancer
Interventions
aromatase inhibition therapy - OBSERVATIONAL ONLY, medical chart review, questionnaire administration, assessment of therapy complications
Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years to 90 Years · Female only
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 9, 2026, 8:58 AM EDT
Terminated Phase 1 Interventional

Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

NCT01491594
View directory record Official record
Conditions
Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue
Interventions
Eltrombopag
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 82 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 9, 2026, 8:58 AM EDT
Completed Early Phase 1 Interventional

Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma

NCT02384473
View directory record Official record
Conditions
Adult Soft Tissue Sarcoma, Bone Sarcoma, Retroperitoneal Sarcoma
Interventions
Real-Time CEUS, SWE, Definity Suspension for Injection, Philips Shear Wave Elastography
Procedure · Drug · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 9, 2026, 8:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

NCT03160274
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions, Kidney Neoplasms, Bone Cancer, Thyroid Neoplasms, Other Cancer
Interventions
Genetic screening
Genetic
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 9, 2026, 8:58 AM EDT